Abstract Number: 1486 • ACR Convergence 2023
Clinical Outcomes in Patients Admitted for ST-Elevation Myocardial Infarction with vs Without Systemic Lupus Erythematosus: An Analysis from National Inpatient Sample Database (2015-2018)
Background/Purpose: Impact of systemic lupus erythematosus (SLE) on the clinical outcomes of patients admitted for ST-elevation myocardial infarction (STEMI).Methods: Patient data was collected for years…Abstract Number: 1979 • ACR Convergence 2023
Weight Loss Induced by Anti-obesity Medications and All-cause Mortality Among Patients with Knee or Hip Osteoarthritis
Background/Purpose: The current international guidelines recommend weight loss for pain relief and functional improvement in overweight or obese patients with knee or hip osteoarthritis; however,…Abstract Number: 0299 • ACR Convergence 2023
Trends and Outcomes of Hospitalized Patients with Idiopathic Inflammatory Myopathy and Venous Thromboembolism: A Nationwide Inpatient Sample Analysis from US (2016-2019)
Background/Purpose: Recent evidence suggests increased prevalence of venous thromboembolism (VTE) in patients with idiopathic inflammatory myopathies (IIM). The literature on the clinical implications of VTE…Abstract Number: 1070 • ACR Convergence 2023
Safety of DMARDs in Rheumatologic Immune-related Adverse Events Associated with Immune Checkpoint Inhibitors: Data from a Monocentric Cohort in Hospices Civils De Lyon
Background/Purpose: Since Immune Checkpoint Inhibitors (ICI) revolution, oncologists face immune-related adverse events (irAEs) including rheumatologic irAEs with inflammatory arthritis. Treatment of rheumatologic irAE can be…Abstract Number: 1499 • ACR Convergence 2023
Year-5 Follow-up of Belimumab Safety (mortality and Malignancies) in Patients with Systemic Lupus Erythematosus (SLE) Who Completed a Phase 4, 52-week, Randomized, Double-blind Placebo-controlled Safety Study
Background/Purpose: Belimumab (BEL) is an approved treatment for active SLE and LN, in addition to standard therapy (ST). Despite BEL clinical studies demonstrating a favorable…Abstract Number: 2115 • ACR Convergence 2023
Genetic Risk Load as a Predictor of Radiographic Damage and Mortality in Female Patients with Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease characterized by an unpredictable prognosis and increased mortality risk. Although the role of genetics in RA mortality…Abstract Number: 0415 • ACR Convergence 2023
Serious Infections Hospital Admissions and Mortality in Patients with Early Inflammatory Arthritis: Results from a Large UK Cohort
Background/Purpose: To identify risk of serious infections (SI) according to initial treatment strategy, using conventional synthetic disease modifying anti-rheumatic drugs (csDMARD) and corticosteroids, in patients…Abstract Number: 1078 • ACR Convergence 2023
Outcomes of COVID-19 Infection in Hospitalized Autoimmune Patients and Transplant Patients on Immunosuppression
Background/Purpose: Coronavirus disease 2019 (COVID-19) can have varying outcomes. Patients with chronic conditions or immunosuppression experience more severe illness. Both organ transplant recipients and patients…Abstract Number: 1513 • ACR Convergence 2023
Trends in Systemic Sclerosis- related Mortality by Age, Sex and Race in the United States, 1999-2019
Background/Purpose: Systemic Sclerosis (SSc) is a rare chronic disease characterized by widespread vascular damage and tissue fibrosis of the skin and various internal organs, which…Abstract Number: 2117 • ACR Convergence 2023
Frailty Is Associated with Mortality in Veterans with Rheumatoid Arthritis
Background/Purpose: Frailty is established as an important predictor of mortality in the general population.1Rheumatoid arthritis (RA) is associated with higher rates of frailty than the…Abstract Number: 0609 • ACR Convergence 2023
Mortality After Autologous Hematopoietic Stem Cell Transplant for Autoimmune Disease: Do Scleroderma Patients Fare Worse?
Background/Purpose: Autologous hematopoietic stem cell transplantation (HSCT) has benefitted some patients with autoimmune disease (AD) but is associated with toxicity and treatment-related mortality. Autologous HSCT…Abstract Number: 1156 • ACR Convergence 2023
Presentations and Outcomes of Idiopathic Inflammatory Myopathies in Hong Kong
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a group of heterogeneous autoimmune diseases with cutaneous, musculoskeletal, and systemic involvements. The Hong Kong Myositis Registry (MyoHK) was…Abstract Number: 1541 • ACR Convergence 2023
Neurologic Involvement Does Not Affect Cumulative Survival Rates in Patients with ANCA-associated Vasculitis and Is Less Commonly Associated with Rapidly Progressive Glomerulonephritis in Patients with GPA
Background/Purpose: The aim of this study was to analyze the incidence of nervous system manifestations in a cohort of patients with Microscopic Polyangiitis (MPA) and…Abstract Number: 2122 • ACR Convergence 2023
Coronary Calcium and Carotid Artery Stiffness as Predictors of Cardiovascular Events and Mortality in Patients with Rheumatoid Arthritis: A 10-year Prospective Follow-up Study
Background/Purpose: The risk of mortality is increased in patients with RA compared to the general population. Different non-invasive surrogate markers of atherosclerosis have been implemented…Abstract Number: 0618 • ACR Convergence 2023
Incident versus Prevalent Interstitial Lung Disease in Systemic Sclerosis in the EUSTAR Database: Different Disease Phenotypes and Prognosis
Background/Purpose: Although 50% of patients with systemic sclerosis (SSc) present with interstitial lung disease (ILD) at baseline, new onset of ILD can also occur later…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 18
- Next Page »